Skip to content
PKI Parkland Fuel Corp TSX
39.49 CAD 0.20% +0.08
OPEN 39.40
DAY RANGE 39.80 - 39.34
52 WEEK RANGE 40.19 - 24.25
Interactive Brokers Logotype

Buy PKI stocks now with Interactive Brokers – the most advanced investment platform

Valuations metrics

Market capitalization 6.9B
Enterprise value 13.1B
Trailing pe 20.567709
Forward pe 12.2260065
Peg ratio 12.2260065
Price to sales ttm 0.20350039
Price to book mrq 2.2541244
Enterprise to revenue 0.384
Enterprise to ebitda 9.186


Fiscal year ends 2022-12-31
Most recent quarter 2023-06-30
Profit margin 0.00964
Operating margin 0.02368
Return on assets ttm 0.03694
Return on equity ttm 0.1238
Income statement
Revenue ttm 34.1B
Revenue per share ttm 200.668
Quarterly revenue growth -0.195
Gross profit ttm 4B
Ebitda 1.4B
Net income to common ttm 329M
Diluted eps ttm 1.92
Quarterly earnings growth yoy -0.037
Balance sheet
Total cash mrq 253M
Total cash per share mrq 1.439
Total debt mrq 6.5B
Total debt to equity mrq 209.61
Current ratio mrq 1.386
Book value per share mrq 17.519
Cash flow
Operating cash flow ttm 1.9B
Levered free cash flow ttm 704.6M

Stock statistics

Shares outstanding 175.8M
Float shares 139M
Avg 10 volume 619K
Avg 30 volume 510.8K
Shares short 864.3K
Short ratio 2.2
Percent held by insiders 0.20411
Percent held by institutions 0.34264

Stock price summary

Fifty two week low 24.25
Fifty two week high 40.19
Fifty two week change 27.045
Beta 1.404864
Day 50 ma 36.8664
Day 200 ma 32.8209

Dividends and splits

Forward annual dividend rate 1.36
Forward annual dividend yield 0.0347
Trailing annual dividend rate 1.33
Trailing annual dividend yield 0.03374778
5 year average dividend yield 3.33
Payout ratio 0.69269997
Dividend date 2023-10-13
Ex dividend date 2023-09-21
Last split factor 3-for-1 split
Last split date 2007-05-23

PerkinElmer (PKI) company profile

PerkinElmer Inc. (NYSE: PKI) is a medical company that provides products, services, and solutions to the diagnostics, life sciences, and applied services markets. It operates through the segments of Discovery & Analytical Solutions, and Diagnostics. The company also develops technologies that enable and support genomic workflows using protein. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies.